US FDA gives more time for electronic safety reporting
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration is delaying until 8 September the deadline for companies to comply with a requirement to electronically submit post-marketing individual case safety reports (ICSRs) of adverse events linked to drugs and biologics1.